Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Alendronic acid
Drug ID BADD_D00066
Description Alendronic acid is a second generation bisphosphonate that is used for the treatment of some forms of osteoperosis and Paget's disease[FDA Label][A959,A203111]. It functions by preventing resorption of bone[FDA Label][A959].
Indications and Usage Alendronic acid is indicated for the treatment and prevention of osteoporosis in men and postmenopausal women, treatment of glucocorticoid-induced osteoporosis, and Paget's disease of bone[FDA Label][A959,A176750]. However, alendronic acid is not indicated for use in pediatric populations or patients with a creatinine clearance <35mL/min[FDA Label].
Marketing Status approved
ATC Code M05BA04
DrugBank ID DB00630
KEGG ID D07119
MeSH ID D019386
PubChem ID 2088
TTD Drug ID D09KLR
NDC Product Code Not Available
UNII X1J18R4W8P
Synonyms Alendronate | 4-Amino-1-Hydroxybutylidene 1,1-Biphosphonate | Aminohydroxybutane Bisphosphonate | MK-217 | MK 217 | MK217 | Alendronate Monosodium Salt, Trihydrate | Alendronate Sodium | Fosamax
Chemical Information
Molecular Formula C4H13NO7P2
CAS Registry Number 66376-36-1
SMILES C(CC(O)(P(=O)(O)O)P(=O)(O)O)CN
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hypergammaglobulinaemia benign monoclonal16.23.01.004; 01.14.01.0040.000044%Not Available
Hypermetropia06.02.04.0100.000044%Not Available
Intervertebral disc displacement15.10.01.0060.000132%Not Available
Jaw cyst16.11.03.002; 15.02.04.0350.000044%Not Available
Jugular vein thrombosis24.01.02.0070.000044%Not Available
Kyphoscoliosis15.10.04.0070.000154%Not Available
Lichen sclerosus23.03.08.006; 21.10.03.0100.000044%Not Available
Lumbar spinal stenosis17.10.03.004; 15.10.04.0080.001035%Not Available
Lymphadenopathy mediastinal22.09.03.006; 01.09.01.0250.000044%Not Available
Meralgia paraesthetica17.09.02.011; 12.01.01.0030.000044%Not Available
Metastases to bone16.22.02.005; 15.09.03.0060.000110%Not Available
Metatarsalgia15.02.01.0070.000132%Not Available
Mitral valve prolapse02.07.01.0080.000418%Not Available
Mood disorder due to a general medical condition19.04.04.0060.000044%Not Available
Nasal turbinate hypertrophy22.04.03.0210.000044%Not Available
Nodal osteoarthritis15.01.04.0060.000088%Not Available
Obstruction gastric07.13.04.0020.000044%
Oesophageal dilatation07.11.02.0050.000044%Not Available
Osteitis deformans15.02.04.0130.000044%Not Available
Osteoma16.11.02.002; 15.09.01.0080.000141%Not Available
Overweight14.03.02.0210.000066%Not Available
Pancreatic carcinoma metastatic16.13.10.003; 07.21.09.0060.000044%Not Available
Pancreatic cyst16.05.01.005; 07.18.03.0030.000044%Not Available
Pelvic mass21.07.04.012; 08.03.05.009; 07.11.01.0280.000044%Not Available
Pernicious anaemia10.04.01.007; 07.17.01.004; 01.03.01.0030.000176%Not Available
Pickwickian syndrome22.02.01.031; 19.02.05.010; 17.15.04.007; 01.07.01.0020.000044%Not Available
Post-traumatic stress disorder19.06.06.0020.000242%Not Available
Renal atrophy20.01.06.0010.000110%Not Available
Seasonal affective disorder19.04.04.0070.000044%Not Available
Slow response to stimuli17.02.05.0630.000044%Not Available
The 33th Page    First    Pre   33 34 35 36 37    Next   Last    Total 39 Pages